| Literature DB >> 28380073 |
Moses K Nyongesa1,2, Antipa Sigilai1,2, Amin S Hassan1, Janet Thoya1, Rachael Odhiambo1, Fons J R Van de Vijver3,4,5, Charles R J C Newton1,6, Amina Abubakar1,2,6.
Abstract
BACKGROUND: Despite bearing the largest HIV-related burden, little is known of the Health-Related Quality of Life (HRQoL) among people living with HIV in sub-Saharan Africa. One of the factors contributing to this gap in knowledge is the lack of culturally adapted and validated measures of HRQoL that are relevant for this setting. AIMS: We set out to adapt the Functional Assessment of HIV Infection (FAHI) Questionnaire, an HIV-specific measure of HRQoL, and evaluate its internal consistency and validity.Entities:
Mesh:
Year: 2017 PMID: 28380073 PMCID: PMC5381886 DOI: 10.1371/journal.pone.0175021
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart of Scoping review.
Characteristics of identified studies.
| Key results/Findings (psychometric properties) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author (s) | Country | Year | Sample Size | Source | PWB α | EWB α | FGWB α | SWB α | CF α | FAHI | Established | Sensitivity | |
| Total α | validity | to change | |||||||||||
| Byrne S. & Petry N. [ | USA | 2012 | n = 170 | Single | 0.85 | 0.89 | 0.82 | 0.70 | 0.70 | 0.92 | Convergent | YES | |
| Discriminant | |||||||||||||
| Peterman A.H. et al [ | USA | 1997 | n = 361 | BIOQoL (n = 110) | Divergent | YES | |||||||
| VCU data (n = 39) | 0.91 | 0.82 | 0.86 | 0.73 | 0.75 | 0.91 | Construct | ||||||
| Multi-center trial (n = 212) | |||||||||||||
| Viala-Danten M. et al [ | USA | 2010 | n = 1661 | POWER trial (n = 565) | 0.91 | 0.83 | 0.89 | 0.85 | 0.75 | NR | Construct | NR | |
| DUET trial (n = 1,091 | 0.92 | 0.84 | 0.89 | 0.84 | 0.72 | NR | |||||||
| Cella D.F. et al [ | USA | 1996 | n = 245 | Stress sample (n = 110) | 0.91 | Concurrent | YES | ||||||
| BIOQoL English (n = 71) | NR | NR | NR | NR | NR | 0.91 | |||||||
| BIOQoL Spanish (n = 64) | 0.92 | ||||||||||||
| Feinberg J. et al [ | USA, Canada | 2011 | n = 429 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
| & Puerto Rico | |||||||||||||
| Earthman C.P. [ | USA | 2002 | n = 25 | Single | 0.91 (7 Item) | NR | NR | NR | NR | NR | NR | NR | |
| Hasanah C.I., Zaliha A.R., | Malaysia | 2010 | n = 271 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
| Mahiran M. [ | |||||||||||||
| Cianfrocca M. et al [ | USA | 2010 | n = 73 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
| Rao D. et al [ | Continental | 2007 | n = 273 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
| United States | |||||||||||||
| & Puerto rico | |||||||||||||
| Abrams D.I, Steinhart C., | USA | 2000 | n = 221 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
| Frascino R. [ | |||||||||||||
| Tomita A et al [ | South Africa | 2013 | n = 160 | Single | 0.88 | 0.83 | 0.85 | 0.72 | 0.65 | 0.86 | NR | NR | |
| Tomita A et al [ | South Africa | 2014 | n = 51 | Single | 0.92 | 0.80 | 0.83 | 0.73 | 0.60 | 0.90 | NR | NR | |
| Diamond C., | USA | 2010 | n = 100 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
| Taylor T.H., | |||||||||||||
| Anton-Culver H. [ | |||||||||||||
| Cella D.F. et al [ | USA | 2010 | n = 1203 | DUET– 1 (n = 612) | NR | NR | NR | NR | NR | NR | NR | NR | |
| DUET– 2 (n = 591) | |||||||||||||
| Sikkema K.J. et al [ | USA | 2005 | n = 235 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
| Winston A. [ | Multi- centered | 2010 | n = 256 | Single | NR | NR | NR | NR | NR | NR | NR | NR | |
BIOQoL-Bilingual Intercultural Oncology Quality of Life, VCU -Virginia Commonwealth University, FAHI–Functional Assessment of HIV infection, PWB–Physical Wellbeing, EWB–Emotional Wellbeing, FWB–Functional and Global Wellbeing, SWB–Social Wellbeing, CF–Cognitive Functioning, POWER–Performance Of TMC114/r When evaluated in treatment-Experienced patients with protease inhibitor Resistance. DUET- a randomized, double-blind, placebo-controlled, phase III trial examining the efficacy, tolerability, and safety of TMC125 in treatment-experienced patients. NR–Not Reported
* Number of patients with all sub scale scores available
Characteristics of study participants—phase II and III.
| Phase II N = 38 | Phase III N = 103 | |
|---|---|---|
| 40.89 (10.42) | 37.37 (7.76) | |
| Female | 27 (71.1%) | 97 (94.2%) |
| Male | 11 (28.9%) | 6 (5.8%) |
| None | 8 (21.1%) | 33 (32.0%) |
| Primary | 19 (50.0%) | 54 (52.4%) |
| Secondary | 11(28.9%) | 12 (11.7%) |
| College | 0 (0%) | 4 (3.9%) |
| Divorced | 1 (2.6%) | 0 (0%) |
| Married | 22 (57.9%) | 59 (57.3%) |
| Separated | 7 (18.4%) | 23 (22.3%) |
| Single | 4 (10.5%) | 4 (3.9%) |
| Widowed | 4 (10.5%) | 17 (16.5%) |
Means, SD, Cronbach’s α and correlation for the adapted FAHI (n = 103).
| Subscale | N of items | Mean | SD | Score Range | Cronbach's α | 95% CI | Correlation with SSQ |
|---|---|---|---|---|---|---|---|
| Physical wellbeing (PWB) | 10 | 14.77 | 3.82 | 0–20 | 0.78 | 0.71–0.84 | |
| Functional & Global wellbeing (FWB) | 13 | 21.09 | 3.69 | 0–26 | 0.71 | 0.62–0.79 | |
| Emotional wellbeing (EWB) | 10 | 15.05 | 3.32 | 0–20 | 0.66 | 0.55–0.75 | |
| Social wellbeing (SWB) | 8 | 10.28 | 3.42 | 0–16 | 0.67 | 0.57–0.76 | |
| Cognitive functioning (CF) | 3 | 4.73 | 1.38 | 0–6 | 0.55 | 0.37–0.68 |
SSQ: Shona Symptoms Questionnaire
*. Correlation is significant at the 0.05 level (1-tailed).
**. Correlation is significant at the 0.01 level (1-tailed).
Factor loadings of adapted FAHI subscale items.
| Subscale and its items | Factor loadings |
|---|---|
| Feeling fatigued | 0.782 |
| Feeling weak all over | 0.688 |
| Getting tired easily | 0.693 |
| Lack of energy | 0.551 |
| Having pain | 0.538 |
| Feeling ill | 0.453 |
| Having nausea | 0.381 |
| Side effects of treatment | 0.349 |
| Trouble meeting the needs of my family due to physical condition | 0.319 |
| Spending time in bed | 0.286 |
| Work fulfillment | 0.604 |
| Enjoying life | 0.590 |
| Content with the quality of my life | 0.556 |
| Enjoying things done for fun | 0.462 |
| Motivation to do things | 0.422 |
| Satisfaction in coping with illness | 0.421 |
| Ability to work | 0.416 |
| Hope for the future | 0.342 |
| Appetite | 0.339 |
| Sexual attractiveness | 0.325 |
| Sleep | 0.311 |
| Loss of hope in fighting illness | 0.245 |
| Acceptance | 0.184 |
| Worry about condition worsening | 0.646 |
| Worry about death | 0.623 |
| Nervousness | 0.571 |
| Embarrassment | 0.499 |
| Unhappy with appearance | 0.501 |
| Sadness | 0.391 |
| Concerned about the future | 0.362 |
| Worry about the effects of stress on illness | 0.248 |
| Disclosure | 0.231 |
| Worry about spreading the infection | 0.147 |
| Emotional support from family | 0.655 |
| Support from friends | 0.523 |
| Satisfaction with sex life | 0.490 |
| Availability of help if needed | 0.501 |
| Closeness to partner or main supporter | 0.430 |
| Satisfaction with family communication | 0.375 |
| Closeness to friends | 0.386 |
| Family acceptance of the illness | 0.248 |
| Trouble remembering things | 0.600 |
| Trouble concentrating | 0.543 |
| Clear thinking | 0.495 |
Factor loadings of adapted FAHI using subscale scores.
| Subscale | Factor loadings |
|---|---|
| Physical wellbeing | 0.601 |
| Functional Global wellbeing | 0.772 |
| Emotional wellbeing | 0.771 |
| Social wellbeing | 0.516 |
| Cognitive functioning | 0.500 |